New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
07:00 EDTAERIAerie Pharmaceuticals shares should be bought ahead of data, says Stifel
After traveling with Aerie's management, Stifel believes there is a good chance that the Phase 2b data for the company's Roclatan will be positive. The firm expects the data to be released in late June/early July, and it recommends buying shares of Aerie ahead of the data release. It keeps a $24 price target and Buy rating on the shares.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 1, 2015
07:19 EDTAERIAerie Pharmaceuticals weakness a buying opportunity, says Brean Capital
Brean Capital believes it is too early to throw in the towel on Aerie Pharmaceuticals and said last week's announcement of Phase 3 trial data for the company's lead glaucoma candidate created a strong buying opportunity. The firm said they are incrementally confident that Rocket 2 would have a better chance of success. Brean Capital reiterated its Buy rating and $24 price target on Aerie Pharmaceuticals shares.
April 24, 2015
14:31 EDTAERIAerie Pharmaceuticals downgraded to Hold from Buy at Needham
Subscribe for More Information
10:11 EDTAERIHigh option volume stocks
10:00 EDTAERIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:20 EDTAERIOn The Fly: Pre-market Movers
UP AFTER EARNINGS: eHealth (EHTH), up 24.7%... Starbucks (SBUX), up 4.2%... Microsoft (MSFT), up 5.2%... Google (GOOG, GOOGL), up 3.2% and up 3.7%, respectively... Amazon (AMZN), up 12% after reporting quarterly results and announcing shopping app for Apple Watch... Gigamon (GIMO), up 16.5%... Juniper Networks (JNPR), up 6.6%. ALSO HIGHER: Molycorp (MCP), up 10.2% following a Bloomberg report that China's export tax decision may boost rare earth demand... Mattel (MAT), up 4.4% after being upgraded to Buy from Neutral at Goldman... Innocoll (INNL), up 13.1% after 3.3M share Secondary priced at $9.00... Cytosorbents (CTSO), up 9.7% after CEO comments on CytoSorb in letter to shareholders. DOWN AFTER EARNINGS: Biogen (BIIB), down 4.7%... Altera (ALTR), down 1.7%... Pandora (P), down 4%... ResMed (RMD), down 8.7%... Xerox (XRX), down 4.7%... HomeAway (AWAY), down 3.6% after reporting quarterly results and departure of officers. ALSO LOWER: Ubiquiti (UBNT), down 14.4% following CFO resignation and preliminary third quarter results... 3D Systems (DDD), down 10.4% after reporting preliminary first quarter results... StemCells (STEM), down 23.2% after filing to sell common stock... Aerie Pharmaceuticals (AERI), down 54.7% after Rhopressa Phase 3 trial did not meet primary endpoint.
08:07 EDTAERIAerie Pharmaceuticals still has significant opportunity, says Stifel
Subscribe for More Information
07:15 EDTAERIAerie Pharmaceuticals weakness overdone, says Brean Capital
Subscribe for More Information
06:36 EDTAERIAerie Pharmaceuticals downgraded to Hold from Buy at Canaccord
Canaccord downgraded Aerie Pharmaceuticals to Hold after Rhopressa, the company's lead glaucoma candidate, missed the primary endpoint in a Phase 3 trial. Note Cantor Fitzgerald also downgraded shares this morning.
06:33 EDTAERIAerie Pharmaceuticals downgraded to Hold from Buy at Cantor
Subscribe for More Information
April 23, 2015
19:16 EDTAERIOn The Fly: After Hours Movers
Subscribe for More Information
16:13 EDTAERIAerie Pharmaceuticals reports Rhopressa Phase 3 did not meet primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use